Pharmacological Management of Gestational Diabetes
An overview
- From the Department of Obstetrics and Gynecology, Brown Medical School, and the Women & Infants Hospital of Rhode Island, Providence, Rhode Island
- Address correspondence and reprint requests to Donald R. Coustan, Chace/Joukowsky Professor and Chair, Department of Obstetrics and Gynecology, Brown Medical School, Obstetrician and Gynecologist in Chief, Women & Infants Hospital of Rhode Island, 101 Dudley St., Providence, RI 02905-2401 E-mail: dcoustan{at}wihri.org
Abstract
OBJECTIVE—To provide a review of the background literature regarding the pharmacological management of gestational diabetes.
RESEARCH DESIGN AND METHODS—This is a literature review.
RESULTS—Information is available regarding the use of some, but not all, oral antidiabetes agents in pregnancy.
CONCLUSIONS—Available evidence supports the use of glyburide during pregnancy. Evidence is inadequate to support or refute the use of metformin, an agent that has been shown to cross the placenta and thus could be helpful or harmful to the developing fetus.
Footnotes
-
This article is based on a presentation at a symposium. The symposium and the publication of this article were made possible by an unrestricted educational grant from LifeScan, Inc., a Johnson & Johnson company.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
-
- Accepted June 14, 2006.
- Received March 28, 2006.
- DIABETES CARE
